Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block
Withdrawn before enrolling · Phase 4
Conditions studied: Pain, Postoperative, Pain, Chest
In brief
The goals of this study are as follows: 1. to confirm the safe dosing of ropivacaine for the erector spinae plane block 2. develop a pharmacokinetic profile of the erector spinae plane block, which will help demonstrate how quickly and how closely toxic levels are reached when a routine dose of ropivacaine is given for this nerve block 3. assess numbness created by the erector spinae block when routine doses are administered
Key facts
- Study ID
- NCT03874806
- Run by
- Virginia Commonwealth University
- People needed
- 0
- Starts
- 2019-07-01
- Expected to finish
- 2020-12-31
- Last updated by the study team
- 2019-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participant's age is greater than 18 years
- Participant is undergoing a primary coronary artery bypass grafting surgery or heart valve replacement that requires a midline sternotomy incision
- Participant's surgery is being performed by Dr. Vig Kasirajan
You may not qualify if…
- Diagnosis of cirrhosis, hepatitis, primary sclerosing cholangitis
- Abnormal liver function tests demonstrated by lab results
- Allergy to lidocaine, ropivacaine, or midazolam
- Morbid obesity, defined as body mass index greater than 40
- Existing skin neuropathy on the chest or back
- Body weight less than 50 kg
- Participant is not able to provide verbal feedback, such as when the participant develops altered mental status or requires prolonged mechanical ventilation and sedation
- Participant remains intubated on post-operative day 1
- Pregnant women
Where it is running
- Virginia Commonwealth University — Richmond, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.